<DOC>
	<DOCNO>NCT00811967</DOCNO>
	<brief_summary>The objective study evaluate superiority treatment PegIntron Rebetol antiviral therapy ( control group ) subject chronic hepatitis C type C compensate cirrhosis . Subjects randomize ratio 2:1 ( Treatment Arm Control Arm ) . Subjects Treatment Arm receive combination therapy PegIntron Rebetol 48 week ; enter 24-week post-treatment Follow-up . Subjects detectable Hepatitis C Virus-RNA Treatment Week 24 discontinue treatment enter Follow-up .</brief_summary>
	<brief_title>Inhibition Disease Progression Hepatitis C-infected Patients With Compensated Liver Cirrhosis ( P03811 ) ( COMPLETED )</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Liver Cirrhosis</mesh_term>
	<mesh_term>Disease Progression</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Peginterferon alfa-2b</mesh_term>
	<criteria>Patients compensate hepatic cirrhosis secondary chronic hepatitis C would meet inclusion criterion would interfere exclusion criterion . Patients ( regardless gender ) take contraceptive measure date inform consent end followup Patients meet criterion test/observation/ investigation 30 day begin treatment . Patients quantitative HCVRNA ( + ) ALT &gt; 40 IU/L Patients classify ChildPugh Classification A , ascites hepatic encephalopathy Prothrombin Time &lt; =3.0 second prolong , total bilirubin &lt; = 1.5 mg/dL direct bilirubin &lt; = 0.7 mg/dL , Albumin &gt; = 3.0 g/dL AFP within normal limit , AFPL3 &lt; = 10 % ，PIVKAII &lt; = 100 mAU/mL Serum creatinine &lt; = upper limit normal , creatinine clearance &gt; = 51 mL/minute Patients fast blood glucose &lt; 110 mg/dL . Thyroidstimulating hormone within normal limit Hemoglobin level &gt; = 12 g/dL，leukocyte count &gt; = 3,000/mm3，neutrophil count &gt; = 1,500 /mm3，platelet count &gt; = 80,000/mm3 Patients weigh 40 kg 100 kg within 60 day prior registration Patients diagnose liver cirrhosis ( fibrosis score : F4 ) base liver biopsy perform within year prior registration able provide liver tissue sample . Patients age 20 70 year time inform consent give write informed consent Patients hospitalize least 14 day initiation treatment . Patients administer pegylated interferon ribavirin past . Patients previously receive treatment IFN least 90 day elapse since end previous treatment time registration study Patients receive treatment within 14 day prior registration injectable preparation contain glycyrrhizin/cysteine/glycyron ( Stronger NeoMinophagen C , etc . ) , shosaikoto Patients antiviral drug antitumor drug , immune regulation therapy ( include steroid administration , radiation therapy ) within 90 day prior registration . [ except topical application external drug ] Patients administer study drug within 180 day prior registration . Patients meet follow criterion screen test HBs antigen positive antinuclear antibody &gt; = 320 time Patients history primary biliary cirrhosis , hepatic failure , hepatocellular carcinoma . Patients etiologies liver disease autoimmune , alcoholic druginduced liver disease Patients history decompensated cirrhosis follow disorder . Ascites , jaundice , bleed varix , esophageal and/or gastric varix need treatment , hepatic encephalopathy , spontaneous bacterial peritonitis . Patients hemophilia Patients history neuropsychiatry disorder depression . Patients history epileptic seizure require treatment Patients history angina pectoris , heart failure , myocardial infarction , uncontrollable hypertension ( diastolic blood pressure : equal 110mmHg ) arrhythmia need treatment . Patients chronic pulmonary disease Patients history autoimmune disease ( Crohn 's disease , ulcerative colitis , chronic rheumatoid arthritis , idiopathic thrombocytopenic purpura , systemic lupus erythematosus , autoimmune hemolytic anemia , scleroderma , etc ) . Patients Hemoglobinopathies ( thalassaemia , sickle cell anemia ) Patients malignant tumor Patients organ transplant ( cornea hair transplant ) . Patients history hypersensitivity interferon preparation , biological product vaccine , nucleoside analog Female patient pregnant nursing ( male patient partner pregnant ) , pregnancy rule serum HCG test conduct screening period Patients specific reaction PEGIFNα2b prick test conduct initiation treatment（Only PEG/R group） Other patient judge investigator ( subinvestigator ) inappropriate inclusion study</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>